San Diego-primarily based Viking Therapeutics marked by itself as a serious competitor from the weight loss drug market in February soon after revealing promising information from a mid-phase demo of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when supplied for a weekly injection and in March the